Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Thank you, operator, and welcome, everyone, to the Medivir AB teleconference. Covering the third quarter of 2026, the third quarter has been a period of focused execution. The external news flow, as you've seen, has been relatively quiet, and I will explain today why that is fully in line with our plan. FLEX-HCC, a randomized phase 2 study with fostroxacitabine bralpamide in second-line Hepatocellular Carcinoma, is recruiting according to plan, as are preparations for the proof-of-concept studies. Studies with MIV-711 in Osteogenesis Imperfecta (OI) and Perthes disease are progressing well, and our outlicensed program projects have taken important steps forward. So with the directed share issue that we completed in July, all three phase two studies are funded and our cash is assessed as sufficient at least into 2030. So before we start, please note the important notice on this slide regarding forward-looking statements, which applies to today's presentation. With me today are Pia Baumann, our Chief Medical Officer, who will take you through Fostrox takeaways from recent scientific congresses, ESMO, and MIV-711. And then Patrik Norgren, our CFO, who will cover the financials. Fredrik Öberg, our Chief Scientific Officer, is also with us here in the room and available for questions. But let's start with the three things we would like you to take away from this quarter. In short, Q3 has been a quarter of execution. First, our program, FLEX-HCC, our randomized phase 2 study comparing fostroxacitabine bralpamide plus lenvatinib with lenvatinib alone in second-line advanced hepatocellular carcinoma, is recruiting according to plan in Korea, and preparations for the proof-of-concept studies with MIV-711 are ongoing. Both Osteogenesis Imperfecta (OI) and Perthes disease are progressing well. Second, our outlicensed projects are taking key steps forward. Vetbiolix's phase two study with MIV-701, or VBX-1000 as they call it in dogs, was almost fully enrolled at the end of the quarter. On September 30th, both Biossil, our partner for remetinostat, and Infex Therapeutics, our partner for MET-X, have made important progress as companies. Our partner for MET-X has made important progress as a company. Third, our financial and IP position. We concluded tranche two. It was approved by the Extraordinary General Meeting on July 20th, and the directed share issue was completed, and through the three capital raises that we have now done since December last year, we have raised 336 million SEK before transaction costs, and we are funded at least into 2030. And then, importantly for Fostrox, we received the US notice of allowance for the fostroxacitabine bralpamide plus lenvatinib combination patent, which, once granted, provides protection until at least April 2041. So, before Pia takes you through the programs. I want to put that into context. And if you look at the news flow, Q3 has been relatively quiet. That is not a sign of lack of progress. It is exactly what our plan looks like at this stage. Over the past year, we have completed the first step of the plan, and through three capital raises since December, we have raised 336 million. And all three phase two studies are funded, and our cash is assessed as sufficient at least into 2030. We dosed the first patient in FLEX-HCC in May, and the study is recruiting according to plan, as is the Phase 1b. Importantly, the phase 1b/2a data were published in Clinical Cancer Research in June. We are now in the second step in terms of execution. As mentioned, the FLEX-HCC study is recruiting according to plan, and preparations for the proof of concept are ongoing. Studies with MIV-711 are also progressing according to plan. And for Perthes disease, the pediatric formulation activities are moving forward very nicely. And at the same time, our partners Vetbiolix, Infex Therapeutics, and Biossil are advancing their programs. As we have communicated before, at no cost to Medivir AB, the milestones we will receive, for example, from Infex Therapeutics are of the more modest kind. But more importantly, it is a very clear sign that the project is moving forward to the initiation of a clinical study and that the partnership between, in this case, Infex Therapeutics and Venus Remedies in India is working well. The third step is delivery and read-out from FLEX-HCC expected during 2027, marking the start of the proof. Proof of concept studies with MIV-711 are coming up and we see progress in our partner programs. So this is where the major value inflection points lie. And our job now is to get there according to plan and hopefully as quickly as possible. So this is our pipeline and all programs, all of them targeting patient populations where there is no approved treatment. Today, we focus on the two green ones in terms of in-house development: fostroxacitabine bralpamide and MIV-711, whereas our partner programs are moving forward at the hands of our partners; I wanted to highlight one element being Biossil, our partner for remetinostat, and the agreement we signed last year in November. They have just recently raised a significant amount of money, 153 million USD, in a financing round led by OpenAI Startup Fund. And clearly, not all of that money will go towards remetinostat. But it equally clearly will enable them to drive that program forward. The MET-X project is also moving forward towards the first clinical phase 1 study in India, triggering the milestone payment that we informed about in the quarterly report today. Regarding Vetbiolix's phase two study with MIV-701, it is almost fully enrolled. And we received some questions on that today. I will return to that study after the Q&A section. And again, in all partner programs, we carry no development costs, but we do retain a meaningful financial upside. So with that said, I will hand over to Pia.
Thank you. Jens and I will start talking about Fostrox, and we can go to the next slide. I just wanted to very briefly go through the scientific rationale for fostrox in HCC. The clinical data we have and what FLEX-HCC will provide are points that Jens has already talked about. So Fostrox, you have already heard this, you can just close your eyes now, but just to level set this so everyone understands what a drug we have. It's an oral prodrug designed for liver cancer. It is activated in the liver, which means that we deliver the active substance, which is troxacitabine, where the tumor is, and keep systemic exposure low. Biopsies from our phase 1b/2 study support this. A study has confirmed this, where the DNA damage is in the tumor tissue, and we could not see any DNA damage in the surrounding healthy liver tissue. And this means that we are sparing the important liver function, allowing it to continue operating effectively. In the phase 1b/2a study, 21 patients with advanced HCC, most of them previously treated with atezolizumab plus bevacizumab. They received fostroxacitabine bralpamide plus lenvatinib as a single-arm treatment, and as a clinician. What I find most convincing is really the consistency of the data we got from this study. The objective response rate was 24%, median time to progression was 10.9 months, and a median overall survival of 13.7 months. And it all pointed in the same direction, consistent with what has been reported. It is consistent with what has been reported in previous second-line studies. The combination was also well tolerated. And only one patient discontinued due to an adverse event. And very important as well is that we did not see an increase in the lenvatinib dose reduction compared to what has been reported with the monotherapy treatment. So what the ongoing FLEX-HCC study will do in this program. First, I would say that the enrollment in FLEX-HCC is according to planned timelines. The plan is to randomize 80 patients with advanced HCC after immunotherapy, and they will receive fostroxacitabine bralpamide plus lenvatinib or lenvatinib. The primary endpoint is response rate. We have already heard that. But the estimated readout is planned during 2027. So next year, what FLEX-HCC will provide is the first randomized data set for fostroxacitabine bralpamide, showing whether the efficacy and safety data points really move in the same direction as we saw in the phase 1B/2A study, and whether the fostroxacitabine bralpamide adds efficacy on top of lenvatinib without adding any toxicity. Those data will really form the basis for a registrational study. And importantly, to understand the treatment algorithm and what the patients have access to, there is still no approved treatment in the second-line, advanced liver cancer setting after immunotherapy. So the need is still very high. You can go to the next slide. So we have talked a bit about FLEX-HCC. But I think it's important to put this study in the context of our development strategy for Fostrox, because it's important to understand what the study is designed to deliver. The phase 1b/2a study gave us a consistent efficacy signal across response rate, time to progression, and overall survival, as I just mentioned, and it was well tolerated. And we also found the recommended phase two dose; FLEX-HCC is the next step. It gives us the first randomized comparison of fostroxacitabine bralpamide plus lenvatinib against lenvatinib alone. It is run by an experienced research consortium in Korea with an estimated readout during 2027. What we are looking for in FLEX-HCC is the direction and the consistency that the response rate, progression-free survival, time to progression, and overall survival all point in the same direction as in the phase 1B/2a, and that Fostrox adds efficacy on top of lenvatinib without adding toxicity. That is the evidence that matters for the next step. So the FLEX-HCC data will really form the basis for a registrational study. And it will also give us advice on the design, the endpoints we should have, the patient population, and the study size. And obviously for our dialogue with regulators, it is very important for discussions with potential partners. So FLEX-HCC is the gateway to partnering and a registrational study, which will take us into pivotal development towards becoming the first approved second-line treatment after immunotherapy. Next slide. So last week was a busy week. We attended ESMO in Madrid and, as always, we did not only listen to the scientific presentations, but we also took the opportunity to discuss the new data that was presented with investigators and experts. To better understand what we need to consider in the development of fostroxacitabine bralpamide. These are the key takeaways. The short version is that the second-line opportunity for fostroxacitabine bralpamide plus lenvatinib remains and our strategy is unchanged. The treatment landscape is stable. Immunotherapy combinations remain the first-line standard, and lenvatinib remains the preferred second-line treatment. The LEAP-012 study showed no overall survival benefit when lenvatinib was added to pembrolizumab plus TACE, and that was in intermediate-stage HCC. And this is important to avoid having this systemic treatment already used in the intermediate stage. So we can ensure that this first-line immunotherapy combination remains in the first-line. The discussed topic at ESMO was GPC3 and the bispecific antibody BGB-B2033 from Biossil. The data are promising, but at the same time, the data are early, with a median follow-up of only 5.5 months, and we did not see any data regarding progression-free survival or overall survival. Naturally, this is due to the very short follow-up. In addition, two important questions remained from the presentation. And that is what is the cutoff that defines GPC3 positivity and what happens to the expression of GPC3 during GPC3-targeted treatment? So there are a couple of questions still remaining. We know that Biossil is starting phase 3 studies across lines of treatment and also across clinical stages. It is a very ambitious program. However, their clear strategic aim is likely to be in first-line, where they want to use the synergy, meaning that the GPC3 expression gets upregulated during anti-PD-1 treatment. They likely want to combine it with their own anti-PD-1, tislelizumab, to get approved in the first-line setting. This is what we strongly believe. So, what does this mean for us? There is still no approved second-line treatment after immunotherapy. And the medical need remains. And with GPC3 bispecific likely moving into first line. Second line after immunotherapy remains open for fostroxacitabine bralpamide plus lenvatinib. Also, with improved first-line treatments, more second-line patients will be eligible for systemic treatment, which means that the Fostrox plus lenvatinib population probably will expand. The experts that we met at ESMO continue to see the strong potential with fostroxacitabine bralpamide in combination with lenvatinib in the second-line setting. So our strategy for fostroxacitabine bralpamide plus lenvatinib is therefore unchanged, and we plan the delivery of the FLEX-HCC study results will be during 2027. And that will be the basis for the registration study. Thank you. And we can move to the next slide. So let's move into MIV-711 where we are developing one molecule into two rare bone indications, both without any approved drug treatment today. And preparations for both of these proof-of-concept studies are progressing according to plan. I will start to say a bit about one of them, Osteogenesis Imperfecta. You can go to the next slide. Just as a reminder. Osteogenesis Imperfecta. Or as it is called, brittle bone disease, is a rare genetic disease. It is about 1 in 15,000 births and it is caused by defective or insufficient collagen production. The result is fragile bones that fracture very easily. This results in deformities, short stature, and chronic pain. And there are approximately 500,000 patients globally that are affected by this disease. And no approved disease-modifying treatment is available. The study shown on this slide is our randomized phase 2 proof-of-concept study, where approximately 20 adult patients with OI who have fractured within the previous five years will be enrolled. They will be randomized 1 to 1 to a high or to a low dose of MIV-711 and treated for 12 months. The endpoints are changes in bone biomarkers, which include bone mineral density. We will also look at pharmacokinetics, safety, and number of fractures, and the preparations for this study are progressing according to plan. We have five sites pre-selected and the eligible patients are largely already known to these hospitals, which supports fast enrollment. The preparation of clinical activities is also well underway, and manufacturing of study drug is on schedule, and we continue to see strong commitment from patient organizations. So we can go to the next slide. So looking at MIV-711 as a whole, the work this quarter, as Jens already mentioned, has been focusing on execution. And here, on the manufacturing and the formulation side, the manufacturing of MIV-711 is progressing according to plan. And for Perthes disease, a pediatric oral formulation is a prerequisite for the proof of concept study. And we are following a thorough evaluation. The remaining step is to select the partner before the formulation work begins. The aim is one pediatric formulation that can serve both Perthes disease and Osteogenesis Imperfecta. When we can go into pediatrics there, the foundation of the program is really unchanged: a third-generation, highly selective cathepsin K inhibitor, where we have seen radiographic benefit in around 250 subjects in phase one and two in osteoarthritis. Proof of concept in these specific animal models. Specific animal models. We have Orphan Drug Designation in both indications and Rare Pediatric Disease Designation in Perthes disease. And with that, I hand back to Jens.
Thank you. And just before we touch on MIV-701, just putting it together again, three phase two studies that we are running, are all fully funded and all of them carry a very clear and distinct value inflection point with FLEX-HCC, the randomized study that has progressed the furthest with the top-line readout in 2027, and again, through the three capital raises since December, we have raised 336 million with the support of both existing and new shareholders. We are well-funded with cash sufficient at least into 2030. Meaning we can focus on execution. So before I hand over to Patrik for the financial numbers, a couple of notes on MIV-701 or VBX-1000, which is our cathepsin K inhibitor outlicensed to the French company Vetbiolix for veterinary use, where they are developing it for periodontitis in dogs and one of several projects moving forward in the quarter. To circle back to information that we provided before, this is the randomized, placebo-controlled study Vetbiolix is running with VBX-1000, or MIV-701, in which client-owned dogs with alveolar bone loss from periodontal disease are randomized to three arms. There is a high dose and a low dose of the study drug versus placebo, with endpoints including bone resorption, CT biomarkers, and bone loss, etc. And at the end of quarter three, i.e. September 30th, 40 dogs had been enrolled toward a target of 45. So the study is almost fully recruited. We have received a couple of questions, as we have previously communicated a target of 51 dogs. So let me explain the difference. The study is designed to have 45, i.e. 15 dogs in each arm, 45 evaluable dogs for the analysis; the earlier figure of 51 was the number of dogs to be recruited, including an allowance for expected dropout. That is a standard operating procedure in clinical studies. And that is the number Vetbiolix originally communicated, 51. And so, going forward, we will communicate. And they are communicating the number that matters for the analysis, i.e. 45 dogs. So there's no change to the study design. There is no change to endpoints or the planned analysis. There is no difference compared to previous. And just as a reminder, periodontitis affects around 80% of dogs over three years of age. There are no approved drugs that can stop bone loss today. And under the agreement, we do retain a financial upside without any development costs of our own. And if the study confirms the earlier proof of concept data, it would be transformational clearly for Vetbiolix, but also with a substantial commercial upside for Medivir AB through royalties and a significant share of any partnering income. So as we are at the end of the quarter, we are almost fully enrolled. We are eagerly looking forward to the top-line results of this study. And with that, I hand over to Patrik Norgren for the financial details of the quarter.
Thank you, Jens. I will present the financial summary for the third quarter 2026. The net turnover for the third quarter was 0.7 million SEK, compared with 0.9 million SEK last year, reflecting lower royalty revenues. The operating loss for the third quarter was 17.1 million SEK, compared with 13.6 million SEK last year. This is mainly due to that. The other external costs were 12.7 million SEK, compared with 8.1 million SEK last year, an increase related to higher costs for clinical studies. However, the personnel costs decreased to 4.0 million SEK from 5.8 million SEK. SEK. The cash flow from operating activities in the third quarter was -14.7 million SEK. The cash flow from financing activities was 9.2 million SEK, mainly reflecting tranche two of the directed share issue, which was approved at the Extraordinary General Meeting on July 20th. The cash balance at the end of the third quarter was almost a quarter of a billion SEK. Medivir AB has a strong financial position, and the cash is assessed to be sufficient, at least into 2030. That assessment does not include any income from outlicensing or fostroxacitabine bralpamide or MIV-711, nor future revenues from our agreements with Vetbiolix and Biossil. With that, I hand back to Jens.
So before we go to Q&A, let me close by looking ahead at our most important value drivers. And then for our own programs, recruitment in FLEX-HCC is continuing, moving toward full enrollment with the primary readout expected next year. And then also the site activation and startup of the proof-of-concept study for MIV-711 in Osteogenesis Imperfecta and in Perthes disease, moving ahead with speed on the pediatric formulation activities, so that we can take the next step towards a proof-of-concept study in that indication as well, and for fostroxacitabine bralpamide, we will, of course, continue to strengthen our IP situation. And I think that we've been very successful thus far, and we are very happy to get the US combination patent or the notice of allowance in July. And once that is granted, that provides protection until at least 2041. And then on the partner side, it is really nice to see that three of our programs are all moving forward in a very good direction, with good speed, with Vetbiolix enrolling 40 out of 45 dogs, i.e. Being almost fully enrolled by the end of the quarter. And then again, just to go back to my previous point, there is no change whatsoever to the study design or what the analysis will look like. So 40 out of 45 evaluable dogs are enrolled. Biossil is preparing its first clinical study with remetinostat, and they are well-financed to do so after their 153 million US dollar raise in September. And then, lastly, we saw Infex Therapeutics' MET-X program moving forward, triggering a new milestone to Infex and also then triggering a modest milestone to Medivir AB. And in all three of these programs, there are no development costs but significant financial upside. So that concludes our presentation. Thank you for listening. I think, operator, we can now open up for Q&A.
If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Richard Romanius from Redeye. Please go ahead.
Good afternoon. I have a few questions, starting with a financial one. What are your assumptions behind the financial runway beyond 2030? It would be interesting to hear a bit more detail on this.
I believe. I believe the key thing to convey, and what we have conveyed, is that with the money we have raised, we have the runway for all three phase 2 studies for the three programs and they are fully funded. And in that financial runway, we are not calculating or including any money from partnering activities, any milestones, etc. . And that will clearly be an important element moving forward as well. But most importantly, we can execute all three phase 2 studies, get the readout, and reach the relevant value inflection points. I think those are the most important elements. And that takes us into 2030.
All right. And regarding MIV-701 for dogs. What are your expectations? Or what do you think your partner would do upon positive results in terms of deal making? And what could that mean for Medivir AB in terms of near-term and long-term income?
I mean, there is always a risk that it becomes a bit speculative. But Vetbiolix, what we can say is clearly Vetbiolix is not a big company. They are a relatively small company. They are running two programs close to pivotal, which they are doing in a very nice fashion, but are they sized to take programs forward towards commercialization? ? No, they are not. We know, and they have already communicated externally, that they are in discussions with the big veterinary players, and there is a strong interest in the program because, for periodontal disease, this would be the first disease-modifying drug in a very common condition. So it clearly has a very significant commercial upside, generating the attention of all the big players. They are having those discussions with them. The bigger companies have also again communicated with Vetbiolix. They have also been very clear to them that they are not looking to do any partnering before randomized data, so the study they are now running and the top-line results we are looking forward to in the near term are what those partners are looking for. So I think that, again, we do not know what they will do. But following positive top-line results from this study, it would be quite natural for them to partner and out-license or take whatever step that would be logical for a company of their size. And then just as you ask that, what does that mean for us? We have no milestones to talk about in the deal, as our financial upside is through revenue sharing. And that is how that deal has been structured. We have a very healthy share from a revenue sharing perspective. Hence our comments that this is where we see a significant commercial upside. So if they were to partner, that would be commercially very beneficial for Medivir AB.
All right. That is very clear. Thanks for answering my questions.
As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. The next question comes from Klaus Palin from DNB Carnegie. Please go ahead.
Hi there.
Thanks for taking my question. This is probably the obvious one that you are not interested in answering, but I will do this anyway and just wonder if you have any comments about the enrollment in the FLEX-HCC study. It is performing better than planned.
So. You know, I am going to answer more or less. It is progressing according to plan at these 12 sites in South Korea. We expect all the patients to be included within the 12-month period outlined in the planning. As you know, we do not report patient numbers quarter by quarter, but we will communicate when the enrollment is complete. So the expectation is that there will be a primary readout in 2027. That is what we can say at this time.
But do you notice any competition when it comes to clinical sites in HCC, in Asia?
We saw the data as well, and we have recognized that these GPC3 bispecifics are starting clinical trials. And as I already said, the data are promising, but they have a very short follow-up. We know that they are planning quite a few clinical trials, but we do believe that their main interest is in first-line treatment. So even if there will be competition. Also in the second-line setting, the FLEX-HCC study that is ongoing has been going on since May. I mean, that is not that far away until it is fully enrolled. So hopefully, it will not impact the enrollment in the study. But we will continue to follow this.
As we have said, it is progressing nicely according to plan. So we have not seen any signs of competition hindering us to date either.
Okay. And then just if you could talk about costs going forward. I guess you are entering a period with more activities. So maybe we should expect costs to increase a little bit compared to Q3.
I mean, as we move towards a proof-of-concept study. As you reach the point where you initiate the study, there will always be upfront costs for startup activities and CMC activities. So yes, I would anticipate a bit more cost because of that, with regards to fostroxacitabine bralpamide, I think. No, the way we structured it, we have taken a reasonable chunk of that cost already. So we are not anticipating that to go up; if anything, it should trend in the other direction. So it is not that we are anticipating a major increase. But clearly with the OI study, that will trigger some clinical and CMC costs.
Okay.
Great. Thank you so much. That is all for me.
There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.
Okay. Thank you. So, before we close the call, let me come back to where we started. We emphasized that this was a quarter of execution, i.e. The news flow. I mean, clearly we always want to come up with as much exciting news flow as possible. This news flow has been relatively quiet, but that has been a good quiet this quarter. It has been fully in line with our plan and with funding in place. We are focusing on moving all the projects forward. As we mentioned, we have said it many times, and we will end by saying it again. The FLEX-HCC study, our lead program, is recruiting according to plan. And what we heard at ESMO confirms the opportunity for fostroxacitabine bralpamide in second-line hepatocellular carcinoma. Our strategy is very much unchanged. And the preparations for our other two proof-of-concept studies are progressing well. And again, outlicensed projects. It is really exciting to see all three projects taking steps forward in a single quarter, and with the Vetbiolix topline results around the corner. We are eagerly looking forward to that outcome, which has the potential for a transformational impact on Vetbiolix, but also offers significant upside. And for us. And with the 247 million SEK in cash funding at least into 2030 and the IP strengthened, we feel we have what we need to reach the value inflection point ahead of us. So with that, I would like to thank our shareholders for their continued confidence. And thank you, everyone, for attending today's call and have a great rest of the day.



















